Stratify and enrich clinical trial populations for high-risk, ctDNA-positive patients most likely to benefit from therapy. MRD tests can help elucidate differences in outcomes on investigational therapeutics based on ctDNA positivity post-surgery, prior to investigational therapy initiation.
*image adapted from Nicholas C. Turner et al. Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial. J Clin Oncol 41, 502-502(2023).